Access Bio, Inc. (KOSDAQ:950130)
5,540.00
-250.00 (-4.32%)
Jun 16, 2025, 3:30 PM KST
Access Bio Revenue
Access Bio had revenue of 21.71B KRW in the quarter ending March 31, 2025, a decrease of -38.17%. This brings the company's revenue in the last twelve months to 99.06B, down -29.61% year-over-year. In the year 2024, Access Bio had annual revenue of 112.46B, down -67.74%.
Revenue (ttm)
99.06B
Revenue Growth
-29.61%
P/S Ratio
1.97
Revenue / Employee
980.79M
Employees
101
Market Cap
194.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.46B | -236.18B | -67.74% |
Dec 31, 2023 | 348.64B | -685.22B | -66.28% |
Dec 31, 2022 | 1,033.86B | 528.75B | 104.68% |
Dec 31, 2021 | 505.11B | 383.31B | 314.71% |
Dec 31, 2020 | 121.80B | 78.74B | 182.86% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
PharmaResearch | 392.31B |
Peptron | 4.30B |